微RNA-182在前列腺癌中的研究进展

Research progress of microRNA-182 in prostate cancer

前列腺癌(PCa)是世界上第二常见的恶性肿瘤。近年来我国PCa发病率呈上升趋势,PCa的早期发现、诊断和治疗非常重要。微RNA(miRNA)是由19~23个核苷酸组成的保守的单链非编码小分子RNA,其被证实在PCa、宫颈癌、膀胱癌等许多人类恶性肿瘤中异常表达,并在恶性肿瘤的发生、发展和转移中起着重要作用。微RNA-182(miR-182)位于人7q32.2染色体,目前已被证实其在PCa中表达上调,并通过多种途径参与PCa的发生发展过程。此外,血清miR-182对于PCa的诊断也有一定的参考价值。同时,结合miR-182表达水平与Gleason评分能更好地评估PCa的进展风险。本文对miR-182参与PCa发生发展的相关机制及其在临床诊断、治疗和预后预测方面的研究进展进行综述,旨在为PCa的早期精准治疗提供新靶点。

Prostate cancer(PCa)is the second most common malignant tumor in the world.In recent years,the incidence of PCa in China is also on the rise.Therefore,early detection,diagnosis and treatment of PCa is very important.MicroRNA(miRNA)is a kind of conservative single-stranded non-coding small molecule RNA composed of 19-23 nucleotides,which has been proved to be abnormally expressed in many human malignant tumors such as PCa,cervical cancer and bladder cancer,and plays an important role in the occurrence,development and metastasis of malignant tumors.MicroRNA-182(miRNA-182),located on human chromosome 7(7q32.2),has been proved to be up-regulated in PCa and involved in the development of PCa through a variety of pathways.In addition,serum miR-182 also has certain reference value for the diagnosis of PCa,and the combination of miR-182 expression level and Gleason score can better assess the risk of PCa progression.This article reviewed the relevant mechanism of miR-182 involved in the occurrence and development of PCa,and its research progress in clinical diagnosis prediction,treatment and prognosis prediction,aiming to provide a new target for the early accurate treatment of PCa.